Most patients in the IRIS Registry and Komodo Database who initiated brolucizumab previously used another form of anti-VEGF treatment, according to research presented at the virtual American Academy of Ophthalmology annual meeting.
Of the 93.7% of patients who began treatment with brolucizumab, 70.8% switched from aflibercept, 14.6% switched from ranibizumab and 14.6% switched from bevacizumab.
Marco A. Zarbin, MD, PhD, FACS, professor at Rutgers New Jersey Medical School, said the results “suggest that unmet needs continue for many patients with wet age-related macular degeneration who
Uncategorized